290 related articles for article (PubMed ID: 27896662)
1. Investigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data.
Meid AD; von Medem A; Heider D; Adler JB; Günster C; Seidling HM; Quinzler R; König HH; Haefeli WE
Drug Saf; 2017 Feb; 40(2):133-144. PubMed ID: 27896662
[TBL] [Abstract][Full Text] [Related]
2. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study.
Khan Q; Ismail M; Khan S
BMC Pharmacol Toxicol; 2017 Dec; 18(1):75. PubMed ID: 29191244
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People.
Franchi C; Ardoino I; Rossio R; Nobili A; Biganzoli EM; Marengoni A; Marcucci M; Pasina L; Tettamanti M; Corrao S; Mannucci PM;
Drugs Aging; 2016 Jan; 33(1):53-61. PubMed ID: 26693921
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients.
Khan Q; Ismail M; Haider I; Ali Z
J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):109-115. PubMed ID: 29458991
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study.
Khan Q; Ismail M; Haider I; Khan F
Int J Clin Pharm; 2017 Dec; 39(6):1256-1264. PubMed ID: 28895028
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia.
Moreno-Gutiérrez PA; Gaviria-Mendoza A; Cañón MM; Machado-Alba JE
Br J Clin Pharmacol; 2016 Aug; 82(2):504-11. PubMed ID: 27060989
[TBL] [Abstract][Full Text] [Related]
7. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.
Das B; Rawat VS; Ramasubbu SK; Kumar B
Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339
[TBL] [Abstract][Full Text] [Related]
8. Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients.
Schächtele S; Tümena T; Gaßmann KG; Fromm MF; Maas R
PLoS One; 2016; 11(5):e0155649. PubMed ID: 27192430
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic Drug-Drug interactions of QT-prolonging drugs in hospitalized psychiatric patients.
Hefner G; Hahn M; Hiemke C; Toto S; Wolff J; Roll SC; Klimke A
J Neural Transm (Vienna); 2021 Feb; 128(2):243-252. PubMed ID: 33417009
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?
Romero J; Baldinger SH; Goodman-Meza D; Engstrom K; Valencia CR; Golive A; Medrano F; Rangasamy S; Makkiya M; Fisher JD; Gross J; Krumerman A; Kim S; Garcia MJ; Di Biase L; Ferrick KJ
J Interv Card Electrophysiol; 2016 Jan; 45(1):37-45. PubMed ID: 26589717
[TBL] [Abstract][Full Text] [Related]
11. CredibleMeds.org: What does it offer?
Woosley RL; Black K; Heise CW; Romero K
Trends Cardiovasc Med; 2018 Feb; 28(2):94-99. PubMed ID: 28801207
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.
Sarganas G; Garbe E; Klimpel A; Hering RC; Bronder E; Haverkamp W
Europace; 2014 Jan; 16(1):101-8. PubMed ID: 23833046
[TBL] [Abstract][Full Text] [Related]
13. QT interval and drug therapy.
Drug Ther Bull; 2016 Mar; 54(3):33-6. PubMed ID: 26966121
[TBL] [Abstract][Full Text] [Related]
14. An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval.
Lorberbaum T; Sampson KJ; Woosley RL; Kass RS; Tatonetti NP
Drug Saf; 2016 May; 39(5):433-41. PubMed ID: 26860921
[TBL] [Abstract][Full Text] [Related]
15. [QTc-prolonging drugs and the risk of sudden death].
Reingardiene D; Vilcinskaite J
Medicina (Kaunas); 2007; 43(4):347-53. PubMed ID: 17485963
[TBL] [Abstract][Full Text] [Related]
16. Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents.
Jardin CG; Putney D; Michaud S
Ann Pharmacother; 2014 Feb; 48(2):196-202. PubMed ID: 24301687
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US.
Tisdale JE; Wroblewski HA; Overholser BR; Kingery JR; Trujillo TN; Kovacs RJ
Drug Saf; 2012 Jun; 35(6):459-70. PubMed ID: 22612851
[TBL] [Abstract][Full Text] [Related]
18. Frequency of high-risk use of QT-prolonging medications.
Allen LaPointe NM; Curtis LH; Chan KA; Kramer JM; Lafata JE; Gurwitz JH; Raebel MA; Platt R
Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):361-8. PubMed ID: 16178046
[TBL] [Abstract][Full Text] [Related]
19. Determinants of torsades de pointes in older patients with drug-associated long QT syndrome: a case-control study.
Goutelle S; Sidolle E; Ducher M; Caron J; Timour Q; Nony P; Gouraud A
Drugs Aging; 2014 Aug; 31(8):601-9. PubMed ID: 24923384
[TBL] [Abstract][Full Text] [Related]
20. [Antiemetics and cardiac effects potentially linked to prolongation of the QT interval: Case/non-case analysis in the national pharmacovigilance database].
Rochoy M; Auffret M; Béné J; Gautier S;
Rev Epidemiol Sante Publique; 2017 Feb; 65(1):1-8. PubMed ID: 27988172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
